While it is currently unknown how these BRAF inhibitors lead to increased FAK activation in these BRAF-mutant cells, the use of a FAK inhibitor in combination with BRAF inhibitors decreased tumor growth more than the use of either inhibitor alone57. Here, PTK2 is linked to neoplasm.